Literature DB >> 2955054

Mononuclear phagocytes as targets for cytolytic T lymphocytes.

J W Young, R M Steinman.   

Abstract

Mouse peritoneal macrophages and human blood monocytes are excellent targets for the assay of cytolytic T lymphocytes that develop in the murine and human mixed leukocyte reactions, respectively. 51Cr release in a standard 4 h assay is equivalent to the best release that is obtained with conA-induced T lymphoblasts. Spontaneous release is consistently less than 20% of the total cell label, and syngeneic macrophages are not lysed. Unlike lymphoblasts, mononuclear phagocytes can be used either as freshly isolated cells or after prolonged periods (1-7 days) in culture.

Entities:  

Mesh:

Year:  1987        PMID: 2955054     DOI: 10.1016/0022-1759(87)90177-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  5 in total

1.  Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells.

Authors:  N Bhardwaj; A Bender; N Gonzalez; L K Bui; M C Garrett; R M Steinman
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

2.  Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells.

Authors:  J W Young; R M Steinman
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

3.  Immunomodulation of mouse macrophage killing of Mycobacterium avium in vitro.

Authors:  R D Hubbard; F M Collins
Journal:  Infect Immun       Date:  1991-02       Impact factor: 3.441

4.  The generation of antigen-specific, major histocompatibility complex-restricted cytotoxic T lymphocytes of the CD4+ phenotype. Enhancement by the cutaneous administration of interleukin 2.

Authors:  G E Hancock; Z A Cohn; G Kaplan
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

5.  Direct activation of CD8+ cytotoxic T lymphocytes by dendritic cells.

Authors:  K Inaba; J W Young; R M Steinman
Journal:  J Exp Med       Date:  1987-07-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.